Zydus Lifesciences

西德斯生命科学

on Monday said it has received approval from the US health regulator to market a drug for the treatment of

周一表示，已获得美国健康监管机构的批准，可上市销售一种用于治疗的药物

irritable bowel syndrome

肠易激综合症

with diarrhoea in adults.

成人腹泻。

The company has received

公司已经收到

tentative approval

暂定批准

from the

来自

US Food and Drug Administration

美国食品药品监督管理局

(USFDA) for

美国食品药品监督管理局 (USFDA)

Rifaximin Tablets

利福昔明片

(550 mg), the drug manufacturing firm said in a regulatory filing.

（550毫克），这家制药公司在监管文件中表示。

Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea (

利福昔明片适用于治疗伴腹泻的肠易激综合症 (

IBS-D

腹泻型肠易激综合症

) in adults.

) 在成人中。

As per the IQVIA MAT March sales data, Rifaximin tablets had an annual sales of USD 2,672.9 million in the US.

根据IQVIA MAT 3月销售数据，利福昔明片在美国的年销售额为2672.9万美元。

Shares of Zydus Lifesciences were trading at Rs 926.05 apiece, 0.41 per cent down from previous close, on BSE.

Zydus Lifesciences 的股票在 BSE 上交易，每股价格为 926.05 卢比，较前一收盘价下跌 0.41%。

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)